Presentation is loading. Please wait.

Presentation is loading. Please wait.

Microbicide Applicator: Overview and Regulatory Issues WHO/ICMR/CONRAD/IPM Regulatory Issues in Microbicide Research October 30, 2007.

Published byMelvin Culbert Modified over 9 years ago

Similar presentations

Presentation on theme: "Microbicide Applicator: Overview and Regulatory Issues WHO/ICMR/CONRAD/IPM Regulatory Issues in Microbicide Research October 30, 2007."— Presentation transcript:

1 Microbicide Applicator: Overview and Regulatory Issues WHO/ICMR/CONRAD/IPM Regulatory Issues in Microbicide Research October 30, 2007

2 Why Look at Delivery Systems? Microbicide gels require an applicator or delivery system for insertion into vagina. Delivery system characteristics impact correct use, dosing, acceptability and product price. Diverse populations will prefer different delivery systems. Need to plan now so a choice of delivery systems available the time of product approval.

3 PATH’s Work on Microbicide Delivery Systems Goal: Advance safe, cost effective delivery systems for microbicides, appropriate for women in low-resource settings. Activities: Advancing optimal vaginal applicators Evaluating SILCS diaphragm

4 PATH’s Vaginal Applicator Activities Consultation with US FDA Dose-delivery studies User compliance and acceptability studies Desk study Safety studies Cost analysis Scan of international manufacturers

5 Primary Applicators in Clinical Trials Most trials using prefilled, single- use, plastic applicators Optimal for clinical trials Ensures correct dose in applicator Blinds to product use Reduces variability between trials Reduces user variability

6 Gel Applicators: Prefilled, Single Use Pros: Commonly used in clinical trials High degree of user acceptance in acceptability literature* Cons: Cost likely higher than user-filled or reusable devices Product use linked to timing of sex--challenge for discreet use Portability, storage, disposal could be a challenge Lack of appropriate designs for rectal use *Cohen 2007, Kilmarx 2006, Whitehead 2006, Morrow 2003, Coetzee 2001, Hardy 1998, LePage 1998. Coitally Dependent

7 Gel Applicators: User Filled, Reusable or Single Use Pros: May provide benefits related to cost Alternative materials (e.g., paper) allow for clean, efficient disposal Reusable design can minimize storage/portability requirements Cons: Potential user concern with hygiene of reusable applicators* Difficult to ensure proper filling/dose delivery Requires additional step for user *Cohen 2007, Bentley 2004, Morrow 2003. Coitally Dependent

8 Clinical Study Confirms Applicator Safety* Objectives Assess effect of applicator on signs and symptoms of irritation of external genitalia, cervix, and vagina as seen on colposcopy after a single use Results No severe cervical or vaginal lesions. HTI single-use, HTI user-filled, and Norden-Pac single-use applicators appear safe from perspective of causing severe or repeated vaginal trauma HTI single-use HTI user-filled Norden-Pac single-use *Brache, 2006

9 Acceptability Study (2003-2004) Objective Characterize women’s PREFERENCES regarding applicator features (cost, reuse versus single use, safety). Results Single use applicator preferred Preference related to perceived quality and safety

10 Sample Applicator Cost Estimates (2004) ApplicatorApplicator filling Microbicide tube + tube filling Total cost per use HTI prefilled10¢25¢–40¢35¢–50¢ Norden-Pac prefilled 4¢6¢–15¢10¢–19¢ Tekpack user-filled (PAPER) 3¢17¢ + 35¢8.2¢* HTI user- filled (plastic) 8¢17¢ + 35¢6¢** * Assuming microbicide tube contains 10 doses and 10 applicators are used. **Assuming microbicide tube contains 10 doses and applicator is reused 10 times.

11 One Option for Alternative Microbicide Delivery User Filled Could lower cost by as much as $0.42 per dose Single Use Addresses concerns about spreading germs Paper Burns easily for disposal Example of a user-filled, paper applicator (TEKPAK, Inc.)

12 Case Study: FDA Consultation for a User-Filled, Paper Applicator Microbicide delivered with a user-filled applicator vs. a prefilled applicator. What data is required to establish equivalence if a sponsor wants to incorporate user-filled applicator in an application for market approval? User-filled, paper applicator

13

14 Possible Scenario for Bridging Studies Phase 3 Clinical Trial Microbicide A + Applicator A Bridging Studies Microbicide A + Applicator B

15 Possible Scenario for Bridging Studies Regulatory Submission Microbicide A + Applicator A, B Phase 3 Clinical Trial Microbicide A + Applicator A Bridging Studies Microbicide A + Applicator B

16 Possible Scenario for Bridging Studies Regulatory Submission Microbicide A + Applicator A, B Product Introduction In India Microbicide A + Applicator A, B

17 Next Steps for Microbicide Delivery Developing standard rectal microbicide applicator Improving dosing with user-filled applicators Evaluating diaphragms for microbicide delivery

18 SILCS Diaphragm: a new single-size cervical barrier Single size fits most women Easy to supply and provide Easy to insert and remove Comfortable for both partners Easy to wash and reuse

19 SILCS Diaphragm Microbicide Delivery System Combines chemical and physical barrier protection Offers dual protection Holds microbicide high in vagina Extends time from gel application to sex May reduce stigma Reduces need for an applicator

20 SILCS Microbicide Delivery System—current research Feasibility/acceptability of applying gel to both sides of diaphragm for added protection Impact of gel volume on women’s experience of handling and acceptability of SILCS Gel volume required on cervical and vaginal sides for comparable coverage/protection Comparative acceptability of different gel application methods when used by couples

21 SILCS Diaphragm and controlled release delivery Preliminary feasibility assessment of SILCS diaphragm as a controlled-release delivery device Laboratory testing for material compatibility Queens University of Belfast

22 Questions for Regulatory Consideration What is the regulatory pathway for seeking approval of an alternative delivery system? What bridging data will be required to confirm equivalence for safety and efficacy with prefilled applicators? How will data required change depending on the delivery system proposed?

23 Questions for Regulatory Consideration How can this guidance be shared with researchers/study sponsors? What next steps are needed to support this discussion among Asian regulatory authorities?

24 Optimizing Microbicide Delivery The more options, the better!

25 Thank you to our Donors ! USAID CONRAD amfAR PATH

26 Jessica Cohen Program Officer jcohen@path.org Maggie Kilbourne-Brook Program Officer mkilbou@path.org www.path.org

Download ppt "Microbicide Applicator: Overview and Regulatory Issues WHO/ICMR/CONRAD/IPM Regulatory Issues in Microbicide Research October 30, 2007."

Similar presentations

Non-randomized studies: Studies with historical controls and the use of Objective Performance Criteria (OPCs) Jeff Cerkvenik Statistics Manager Medtronic,

Non-randomized studies: Studies with historical controls and the use of Objective Performance Criteria (OPCs) Jeff Cerkvenik Statistics Manager Medtronic,
Susan Boynton, VP, Global Regulatory Affairs, Shire

Susan Boynton, VP, Global Regulatory Affairs, Shire
Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.

Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.
Atypical Actives PDA-FDA Conference March 9-10, 2011 David R. Schoneker

Atypical Actives PDA-FDA Conference March 9-10, 2011 David R. Schoneker
Strengthening the Medical Device Clinical Trial Enterprise

Strengthening the Medical Device Clinical Trial Enterprise
Essential Steps to Safe, Clean Care Essential Steps AIM: Designed as a framework to support local organisations providing and commissioning health and.

Essential Steps to Safe, Clean Care Essential Steps AIM: Designed as a framework to support local organisations providing and commissioning health and.
Public Health Issues Related to Mutually Conforming Labeling: CDRH Perspective Miriam C. Provost, Ph.D. Office of Device Evaluation Center for Devices.

Public Health Issues Related to Mutually Conforming Labeling: CDRH Perspective Miriam C. Provost, Ph.D. Office of Device Evaluation Center for Devices.
Combination Products and Mutually Conforming Labeling David Eveleth Pfizer Inc.

Combination Products and Mutually Conforming Labeling David Eveleth Pfizer Inc.
October 3, 2006TCBC Meeting October, 2006Slide 1 TCB Code of Practice Art Wall

October 3, 2006TCBC Meeting October, 2006Slide 1 TCB Code of Practice Art Wall
1 FDA Update - CDRH Markham C. Luke, MD PhD Deputy Director for Clinical Office of Device Evaluation, CDRH, FDA May 15, 2012 NORD Corporate Council.

1 FDA Update - CDRH Markham C. Luke, MD PhD Deputy Director for Clinical Office of Device Evaluation, CDRH, FDA May 15, 2012 NORD Corporate Council.
SPONSOR of 4R Nutrient Stewardship Program. The Nature Conservancy Teaming with the Florida agriculture industry to increase farmer profitability and.

SPONSOR of 4R Nutrient Stewardship Program. The Nature Conservancy Teaming with the Florida agriculture industry to increase farmer profitability and.
Www.aids2014.org Getting from Point A to Point B: What it means to bring HIVST to market Petra Stankard Technical Advisor 22 July 2014.

Getting from Point A to Point B: What it means to bring HIVST to market Petra Stankard Technical Advisor 22 July 2014.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
1 A Bayesian Non-Inferiority Approach to Evaluation of Bridging Studies Chin-Fu Hsiao, Jen-Pei Liu Division of Biostatistics and Bioinformatics National.

1 A Bayesian Non-Inferiority Approach to Evaluation of Bridging Studies Chin-Fu Hsiao, Jen-Pei Liu Division of Biostatistics and Bioinformatics National.
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,

Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,
Chapter 13 Commercialization.

Chapter 13 Commercialization.
QUALITY MANAGEMENT SYSTEM ACCORDING TO ISO

QUALITY MANAGEMENT SYSTEM ACCORDING TO ISO
Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.

Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.
1 Regulatory Concepts for Dual Indication Combination Products Charu Mullick, M.D. Division of Antiviral Products, CDER U.S. Food and Drug Administration.

1 Regulatory Concepts for Dual Indication Combination Products Charu Mullick, M.D. Division of Antiviral Products, CDER U.S. Food and Drug Administration.

Similar presentations

Ads by Google